Table 3.

Predicted Sensitivity According to NGS

Predicted Sensitivity	Best Response	Arm	Tumor Location	PTCH1	SMO	hTERT Promoter	Patient ID
	under Vismodegib			(AF%)	(AF%)	(AF%)
S	PR	A	Extra	p.Leu744fs (95%)	WT	c.-124C>T (69%)	3.1
			CNS	p.Lys163* (73%)	WT	c.-124C>T (60%)	3.7
		C	CNS	p.Asn386fs (93%)	WT	c.-146C>T (61%)	3.2
	SD	A	Extra	p.Tyr446* (95%)	WT	c.-124C>T (52%)	1.6
		C	Extra	p.Gln160* (82%)	WT	c.-124C>T (69%)	2.3
			Extra	p.Arg135* (95%)	WT	c.-124C>T (50%)	3.5
			Extra	p.Pro643fs (49%); c.-60 + 2-60 + 3insTT (43%)	WT	c.-124C>T (100%)	5.2
	PD	A	CNS	p.Tyr381fs (41%); p.Glu539fs (45%)	WT	c.-124C>T (63%)	3.4
		B	CNS	p.Asp635fs (24%); p.Gln242fs (62%)	WT	c.-124C>T (49%)	1.1
			Extra	p.Arg770* (40%); p.Glu1095* (50%)	WT	NI	3.3
		C	CNS	p.Trp926* (95%)	WT	c.-124C>T (70%)	1.3
R	PR	C	Extra	WT	p.Leu412Phe (44%)	c.-124C>T (56%)	5.1
	SD	A	Extra	WT	p.Leu412Phe (37%)	NI	8.1
	PD	A	CNS	WT	WT	c.-124C>T (29%)	1.7
		B	CNS	WT	WT	c.-124C>T (73%)	8.2
		C	Extra	WT	WT	c.-146C>T (67%)	1.4
			CNS	WT	p.Leu412Phe (25%)	c.-124C>T (60%)	2.2
			CNS	WT	WT	c.-146C>T (100%)	3.6
UK	PR	A	CNS	WT	p.Gly416Asp (33%)	c.-124C>T (51%)	1.2
			CNS	WT	p.Ile408Val (17%); p.Ser278Ile (15%)	c.-124C>T (69%)	1.5
	SD	A	CNS	N/A	N/A	N/A	9.1
	PD	A	Extra	N/A	N/A	N/A	2.1
		B	CNS	p.Asp879fs (86%)	p.Ala524Pro (47%)	c.-124C>T (86%)	2.4
			CNS	N/A	N/A	N/A	6.1

Abbreviations: AF%, allelic frequency; CNS, central nervous system; N/A, not available; NI, not informative; PD, progressive disease; PR, partial response; R, resistant; S, sensitive; SD, stable disease; WT, wild type.

*The protein coding sequence ends at a translation termination codon (stop codon).